Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 7:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 2,840 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Melanoma, Stage III Mucosal Melanoma of the Head and Neck, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Stage IVA Mucosal Melanoma of the Head and Neck, Stage IVB Mucosal Melanoma of the Head and Neck, Stage IVC Mucosal Melanoma of the Head and Neck
Interventions
Aldesleukin, Laboratory Biomarker Analysis, Pembrolizumab
Biological · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Maywood, Illinois • Bloomington, Indiana • Boston, Massachusetts + 2 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
70 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Long Beach, California + 3 more
Conditions
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Breast Cancer, Breast Neoplasms
Interventions
hMN14 (labetuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Melanoma
Interventions
Tasisulam-sodium, Paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Conditions
Immune Checkpoint Inhibitors, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Gastrointestinal Cancer, Squamous Cell Carcinoma
Interventions
Immunotherapy
Biological
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • Albuquerque, New Mexico • Oklahoma City, Oklahoma + 3 more
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
Interventions
Sacituzumab govitecan
Drug
Lead sponsor
Reshma L. Mahtani, D.O.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Fairway, Kansas
Conditions
Breast Cancer
Interventions
Bevacizumab, Abraxane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Phase II Dasatinib Study in Advanced Breast Cancer

NCT00546104
Conditions
Advanced Breast Cancer
Interventions
Dasatinib
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
West Palm Beach, Florida • Charlotte, North Carolina • Durham, North Carolina
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, therapeutic autologous lymphocytes, aldesleukin, immunohistochemistry staining method, biopsy, laboratory biomarker analysis, immunologic technique, polymerase chain reaction
Drug · Biological · Other + 2 more
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Conditions
HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
NRM-823
Drug
Lead sponsor
Normunity AccelCo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more
Conditions
Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
Interventions
PF-08046031
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 1 more
Conditions
Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary
Interventions
CC-486, Vidaza
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more
Conditions
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
Interventions
NC762
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 5 more
Conditions
Uveal Melanoma
Interventions
AEB071, MEK162
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Breast Cancer
Interventions
YM155, Docetaxel
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Pleasant Hill, California • Lakeland, Florida + 4 more
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Dietary Intervention, Educational Activity, Glucose Measurement, Ketone Measurement, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Unresectable or Metastatic Melanoma
Interventions
Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Conditions
Malignant Melanoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 47 more
Conditions
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Interventions
Azacitidine, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma
Interventions
gp100, R848 gel, MAGE-3
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
Interventions
Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab, Liposomal Doxorubicin, Sacituzumab Govitecan
Biological · Drug
Lead sponsor
Laura Huppert, MD, BA
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
Conditions
Metastatic Breast Cancer
Interventions
Supportive Care
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
HER2 Positive Metastatic Breast Cancer
Interventions
ARX788
Drug
Lead sponsor
Ambrx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more